Back to top

Lexicon lowers 2025 operating expense guidance to $105M-$115M as R&D pivot advances

Lexicon lowers 2025 operating expense guidance to $105M-$115M as R&D pivot advances

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Lexicon Pharmaceuticals, Inc. (LXRX)